AR032553A1 - Derivados de alfa-amino-n-hidroxi-acetamida. - Google Patents
Derivados de alfa-amino-n-hidroxi-acetamida.Info
- Publication number
- AR032553A1 AR032553A1 ARP020100398A ARP020100398A AR032553A1 AR 032553 A1 AR032553 A1 AR 032553A1 AR P020100398 A ARP020100398 A AR P020100398A AR P020100398 A ARP020100398 A AR P020100398A AR 032553 A1 AR032553 A1 AR 032553A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- amino
- triazol
- acetamide
- hydroxi
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 1,2,3 -triazol-2-yl Chemical group 0.000 abstract 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 abstract 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- VDBCTDQYMZSQFQ-UHFFFAOYSA-N glycine hydroxamate Chemical class NCC(=O)NO VDBCTDQYMZSQFQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103303.4A GB0103303D0 (en) | 2001-02-09 | 2001-02-09 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032553A1 true AR032553A1 (es) | 2003-11-12 |
Family
ID=9908475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100398A AR032553A1 (es) | 2001-02-09 | 2002-02-07 | Derivados de alfa-amino-n-hidroxi-acetamida. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7112611B2 (OSRAM) |
| EP (1) | EP1360175A1 (OSRAM) |
| JP (1) | JP4262982B2 (OSRAM) |
| CN (1) | CN100509773C (OSRAM) |
| AR (1) | AR032553A1 (OSRAM) |
| AU (1) | AU2002249197A1 (OSRAM) |
| CA (1) | CA2435611C (OSRAM) |
| GB (1) | GB0103303D0 (OSRAM) |
| PE (1) | PE20020845A1 (OSRAM) |
| WO (1) | WO2002064552A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| GB0103303D0 (en) * | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
| MX2008012387A (es) * | 2006-03-29 | 2008-10-09 | Novartis Ag | Inhibidores selectivos de mmp basados en hidroxamato. |
| US20100234378A1 (en) * | 2006-08-22 | 2010-09-16 | Array Biopharma Inc. | Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors |
| WO2008147764A1 (en) * | 2007-05-23 | 2008-12-04 | Array Biopharma, Inc. | Mmp inhibitors and methods of use thereof |
| CN105101979B (zh) | 2012-12-21 | 2021-10-08 | 安斯泰来再生医药协会 | 由多能干细胞制备血小板的方法及其组合物 |
| US20180353174A1 (en) * | 2017-06-13 | 2018-12-13 | Ethicon Llc | Surgical Stapler with Controlled Healing |
| US10939911B2 (en) | 2017-06-13 | 2021-03-09 | Ethicon Llc | Surgical stapler with end effector coating |
| JP2020523132A (ja) * | 2017-06-13 | 2020-08-06 | エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ | 広域スペクトルｍｍｐ阻害剤を有する手術用締結具 |
| US11058804B2 (en) | 2017-06-13 | 2021-07-13 | Ethicon Llc | Surgical fastener device for the prevention of ECM degradation |
| JP7143334B2 (ja) * | 2017-06-13 | 2022-09-28 | エシコン エルエルシー | 治癒を制御させる手術用ステープラ |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2513826A (en) | 1946-12-05 | 1950-07-04 | Gen Aniline & Film Corp | Aromatic sulfonhydrazides |
| US4772733A (en) | 1986-07-17 | 1988-09-20 | Hercules Incorporated | Epoxy-azides |
| US4806528A (en) | 1987-09-04 | 1989-02-21 | Hanreich Reinhard G | Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide |
| US5338755A (en) | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
| FR2682498A1 (fr) | 1991-10-15 | 1993-04-16 | Kodak Pathe | Colorants comprenant des macrocycles thioethers. |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5646167A (en) | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| GB9503749D0 (en) | 1995-02-24 | 1995-04-12 | British Biotech Pharm | Synthesis of hydroxamic acid derivatives |
| CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| JP3628335B2 (ja) * | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
| SK282863B6 (sk) | 1996-05-17 | 2002-12-03 | Warner-Lambert Company | Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze |
| WO1997045402A1 (fr) | 1996-05-24 | 1997-12-04 | Ono Pharmaceutical Co., Ltd. | Derives de phenylsulfonamide |
| WO1998018754A1 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
| MXPA99001974A (es) | 1996-12-09 | 2002-03-27 | Warner Lambert Co | Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular. |
| US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| GB9708133D0 (en) | 1997-04-22 | 1997-06-11 | British Biotech Pharm | Novel use of matrix metalloproteinase inhibitors |
| EP0877019B1 (de) | 1997-05-09 | 2001-12-12 | Hoechst Aktiengesellschaft | Substituierte Diaminocarbonsäuren |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| HUP0004595A3 (en) | 1997-07-31 | 2001-12-28 | Procter & Gamble | Acyclic metalloprotease inhibitors |
| IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
| CN1195735C (zh) | 1998-02-04 | 2005-04-06 | 诺瓦提斯公司 | 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物 |
| JPH11236369A (ja) * | 1998-02-23 | 1999-08-31 | Kotobuki Seiyaku Kk | スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物 |
| PA8469301A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimientos para la preparacion de acidos hidroxamicos. |
| EP1149072B1 (en) | 1998-12-22 | 2004-06-30 | F. Hoffmann-La Roche Ag | Sulfonamide hydroxamates |
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| AR035311A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
| GB9918684D0 (en) * | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| GB0103303D0 (en) * | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2001
- 2001-02-09 GB GBGB0103303.4A patent/GB0103303D0/en not_active Ceased
-
2002
- 2002-02-07 AR ARP020100398A patent/AR032553A1/es unknown
- 2002-02-07 PE PE2002000088A patent/PE20020845A1/es not_active Application Discontinuation
- 2002-02-08 CN CNB028047133A patent/CN100509773C/zh not_active Expired - Fee Related
- 2002-02-08 AU AU2002249197A patent/AU2002249197A1/en not_active Abandoned
- 2002-02-08 JP JP2002564485A patent/JP4262982B2/ja not_active Expired - Fee Related
- 2002-02-08 WO PCT/EP2002/001345 patent/WO2002064552A1/en not_active Ceased
- 2002-02-08 EP EP02718115A patent/EP1360175A1/en not_active Withdrawn
- 2002-02-08 US US10/467,611 patent/US7112611B2/en not_active Expired - Fee Related
- 2002-02-08 CA CA2435611A patent/CA2435611C/en not_active Expired - Fee Related
-
2006
- 2006-08-07 US US11/500,138 patent/US7291634B2/en not_active Expired - Fee Related
-
2007
- 2007-10-05 US US11/868,032 patent/US7659293B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1525956A (zh) | 2004-09-01 |
| JP4262982B2 (ja) | 2009-05-13 |
| JP2004523545A (ja) | 2004-08-05 |
| US7291634B2 (en) | 2007-11-06 |
| WO2002064552A8 (en) | 2002-12-12 |
| GB0103303D0 (en) | 2001-03-28 |
| CA2435611C (en) | 2011-07-12 |
| US7112611B2 (en) | 2006-09-26 |
| AU2002249197A1 (en) | 2002-08-28 |
| US20080176916A1 (en) | 2008-07-24 |
| US7659293B2 (en) | 2010-02-09 |
| US20060270719A1 (en) | 2006-11-30 |
| CN100509773C (zh) | 2009-07-08 |
| CA2435611A1 (en) | 2002-08-22 |
| EP1360175A1 (en) | 2003-11-12 |
| PE20020845A1 (es) | 2002-10-30 |
| WO2002064552A1 (en) | 2002-08-22 |
| US20040082630A1 (en) | 2004-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
| DK1361882T3 (da) | 4-fluor-N-indan-2-ylbenzamid og dets anvendelse som farmaceutisk middel | |
| ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| SE0200979D0 (sv) | New compounds | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| ES2155473T3 (es) | Composicion veterinaria que contiene un inhibidor de las bombas de protones. | |
| GT200200272A (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino] quinazolin-6-il} alil)acetamidayprocedimiento para la produccion | |
| PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
| ATE381535T1 (de) | Phenethanolaminderivate | |
| BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR032553A1 (es) | Derivados de alfa-amino-n-hidroxi-acetamida. | |
| ECSP034883A (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
| BR0307588A (pt) | Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença | |
| AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación | |
| HRP20030907B1 (hr) | Farmaceutska kompozicija na bazi makrolida za lokalnu upotrebu u oftalmologiji | |
| MX9304503A (es) | Compuestos antiinflamatorios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |